RxDoctor Payments Data

Albert Przybylski, DO

Family Medicine · Clinton Twp, MINPI 1013988773

Payments from drug & device makers

$11,598in general payments, 2019–2025

Across 710 payments — averaging $16.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$2K
  • AstraZeneca$1K
  • GSK$1K
  • Boehringer Ingelheim$1K
  • AbbVie$978
  • Lilly USA, LLC$970
  • plus $4K from 40 others

What the payments were for

  • Food & beverage$11,598100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$11,598 in reported general payments places this provider in the 95th percentile of 3,945 family medicine providers in Michigan.

See all family medicine providers in Michigan

Medicare billing

Part B allowed, 2024
$175,872
Medicare patients
375
Services billed
3,463

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban88$115,148
TrulicityDulaglutide61$101,060
OzempicSemaglutide45$96,931
FarxigaDapagliflozin Propanediol66$66,561
JardianceEmpagliflozin42$61,217
Trelegy ElliptaFluticasone/Umeclidin/Vilanter47$58,237
MounjaroTirzepatide38$53,733
Repatha SureclickEvolocumab18$27,089
XareltoRivaroxaban22$23,959
JanuviaSitagliptin Phosphate11$16,486
MyrbetriqMirabegron15$16,176
Lantus SolostarInsulin Glargine,hum.Rec.Anlog46$8,004
Atorvastatin Calcium476$7,362
TradjentaLinagliptin11$5,486
BrilintaTicagrelor13$5,465

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity, Mounjaro$970$154,79399 claims
PfizerEliquis$813$115,14888 claims
Novo NordiskOzempic$1,861$96,93145 claims
AstraZenecaFarxiga, Brilinta$1,375$72,02679 claims
Boehringer IngelheimJardiance, Tradjenta$1,024$66,70253 claims
GSKTrelegy Ellipta$1,131$58,23747 claims
Johnson & JohnsonXarelto$81$23,95922 claims
MerckJanuvia$134$16,48611 claims
Astellas Pharma US IncMyrbetriq$169$16,17615 claims
AbbVieSynthroid$978$2,52725 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,945 family medicine providers in Michigan.

Other family medicine in Clinton Twp

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →